Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Letter to HRSA on 340B Rebate Model
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
Learn more
CSBA Letter to Congressional Leadership on…
Learn more
BIO Comments to the USPTO’s MAY 10, 2024 Proposed…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
Cures Acceleration Network: BIO Strongly Supports the CAN Program
March 10, 2016
Implementation of CAN will help NIH-funded researchers bridge the precarious gap between basic research and the eventual development of new cures and treatments for many of the diseases we face today.
Pilot Circuit Breaker Proposal: SEC issues proposal on pilot circuit breaker program to combat abusive short selling
March 10, 2016
BIO commends the SEC on its pilot circuit breaker proposal and urges the use of biotech companies in such proposal
Cures Acceleration Network: Patient Group Letter
March 10, 2016
The letter, signed by approximately 85 patient groups, requests appropriation for CAN in FY2011
Technological Innovation Program (TIP): NIST proposes new program support, promote, and accelerate innovation in the United States through high-risk, high-reward research in areas of critical national need.
March 10, 2016
BIO applauds NIST on implementation of TIP program and urges that personalized medicine be included as an area of "critical national need"
Sarbanes-Oxley in Financial Services Compromise: Sarbanes-Oxley 404(b) Legislative Text in the Wall Street Reform and Consumer Protection Act of 2009
March 10, 2016
BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies.
IFRS Roadmap: SEC requests comments on U.S. conversion to a set of global accounting standards
March 10, 2016
BIO provides comment letter to SEC generally supporting the IFRS roadmap while maintaining safeguards for emerging companies during transition.
Letter to the Honorable John Carey
March 10, 2016
Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.
Letter to Governor Deval Patrick
March 10, 2016
BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.
BIO Testimony regarding Oregan Senate Bill 570
March 10, 2016
Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.
Questions for the District of Columbia Board of Pharmacy for the drafting of SafeRx
March 10, 2016
Frequently Asked Questions Document